Phase 3 ARTISTRY-1 and ARTISTRY-2 data support an NDA for a single-tablet HIV regimen combining a capsid inhibitor …
Phase 3 ARTISTRY-1 and ARTISTRY-2 data support an NDA for a single-tablet HIV regimen combining a capsid inhibitor …
A single dose of the lysergide orally disintegrating tablet achieved statistically significant MADRS improvement at six weeks compared …
Capivasertib plus abiraterone and prednisone clears regulatory hurdle for a molecularly defined patient population with limited prior options, …
Tebipenem pivoxil hydrobromide clears regulatory hurdle on resubmission, offering hospitalized patients an oral alternative to intravenous imipenem-cilastatin
The acquisition, announced in March and targeting Centessa’s orexin receptor agonist programme, signals Lilly’s intention to build a …
Shionogi’s ensitrelvir becomes the only approved oral option for preventing COVID-19 following known exposure, filling a gap left …
Arvinas’s vepdegestrant (VEPPANU) marks a regulatory milestone as the first proteolysis-targeting chimera to win FDA approval, offering a …
The FDA approval of Xocova marks a new front in the antiviral arsenal, shifting from treatment to prevention …
The stealth-mode startup emerges with a pipeline targeting focal epilepsy, schizophrenia, tinnitus, and reversible encephalopathy — all acquired …
The U.S. Food and Drug Administration has approved VEPPANU (vepdegestrant), marking a significant milestone as the first PROTAC …
Already a subscriber? Log in